SEP 01, 2020 3:18 PM PDT

First Novel Compounds to Inhibit Cancer-Linked Enzymes

WRITTEN BY: Nouran Amin

Researchers from the University of Michigan Rogel Cancer Center have worked on creating a therapeutic-based compound that can block the activity of cancer-linked enzymes. The particular family of enzymes examined in the study is known as the nuclear receptor-binding SET domain (NSD). The enzymes are part of a family of histone methyltransferases that have long been studied as an attractive drug target. However, the efforts to attack the activity of these enzymes have been challenging because of the shape of the binding sites where drug-like molecules are supposed to attach.

Learn more about enzymatic activity in cancer:

To develop the first-in-class inhibitors, Tomasz Cierpicki, Ph.D., and Jolanta Grembecka, used multiple approaches including X-ray crystallography and nuclear magnetic resonance. The work has led to the inhibition of a key protein known as NSD1. Specifically, they developed a compound known as ‘BT5’ and was shown promise in leukemic cells.

Findings were published in Nature Chemical Biology.

"Our study, which was years in the making, demonstrates that targeting this key enzyme with small-molecule inhibitors is a feasible approach," says Cierpicki, an associate professor of biophysics and pathology at U-M. "These findings will facilitate the development of the next generation of potent and selective inhibitors of these enzymes, which are overexpressed, mutated or undergo translocations in several types of cancer."

Source: Science Daily

About the Author
Master's (MA/MS/Other)
Nouran is a scientist, educator, and life-long learner with a passion for making science more communicable. When not busy in the lab isolating blood macrophages, she enjoys writing on various STEM topics.
You May Also Like
JAN 03, 2023
Cell & Molecular Biology
From sample collection straight to RT-qPCR
From sample collection straight to RT-qPCR
Skip the nucleic acid purification step in your cancer detection workflow. Learn more about how Thermo Fisher Scientific ...
NOV 29, 2022
Drug Discovery & Development
75g Kale Per Day Could Keep Bone Fractures Away
75g Kale Per Day Could Keep Bone Fractures Away
Vitamin K1- a nutrient found in leafy greens like kale, cabbage, and spinach- may help reduce bone fracture risk in elde ...
DEC 11, 2022
Drug Discovery & Development
Novel Dermatitis Treatment Produces Long-Term Results in Clinical Trials
Novel Dermatitis Treatment Produces Long-Term Results in Clinical Trials
A monoclonal antibody drug known as rocatinlimab produced significant results in patients with moderate to severe atopic ...
DEC 14, 2022
Cannabis Sciences
Cannabis Media Coverage Generally Positive Regardless of Clinical Outcome
Cannabis Media Coverage Generally Positive Regardless of Clinical Outcome
A study published in JAMA Open Network shows that cannabis receives significant media coverage regardless of the clinica ...
JAN 03, 2023
Clinical & Molecular DX
Antimicrobial Peptides: The Solution to Antimicrobial Resistance?
Antimicrobial Peptides: The Solution to Antimicrobial Resistance?
According to the World Health Organization, antimicrobial resistance is among the top ten global health threats facing h ...
JAN 06, 2023
Drug Discovery & Development
Shellfish - the new method to prevent unwanted pregnancies
Shellfish - the new method to prevent unwanted pregnancies
A sugar that is created by shellfish may be the next best way to prevent unwanted pregnancies.  According to a 2022 ...
Loading Comments...